IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12 October 2018
|
| In: |
European Journal of Rheumatology
Year: 2018, Volume: 5, Issue: 4, Pages: 230-234 |
| ISSN: | 2148-4279 |
| DOI: | 10.5152/eurjrheum.2018.18036 |
| Online Access: | Verlag: http://www.eurjrheumatol.org/en/il1-blocking-therapy-in-colchicine-resistant-familial-mediterranean-fever-133159 Resolving-System, Volltext: https://doi.org/10.5152/eurjrheum.2018.18036 
|
| Author Notes: | Birgit Maria Köhler, Hanns-Martin Lorenz, Norbert Blank |
| Summary: | Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab. |
|---|---|
| Item Description: | Die angegeben DOI ist nicht mit dem Artikel verlinkt Gesehen am 06.12.2019 |
| Physical Description: | Online Resource |
| ISSN: | 2148-4279 |
| DOI: | 10.5152/eurjrheum.2018.18036 |